Prevalence of insomnia (symptoms) in T2D and association with metabolic parameters and glycemic control: meta-analysis.
We aimed to determine the prevalence of insomnia and insomnia symptoms and its association with metabolic parameters and glycemic control in people with T2D in a systematic review and meta-analysis. A systematic literature search was conducted in Pubmed/Embase until March, 2018. Included studies described prevalence of insomnia or insomnia symptoms and/or its association with metabolic parameters or glycemic control in adults with T2D. Data extraction was performed independently by two reviewers, on a standardized, pre-piloted form. An adaptation of Quality Assessment Tool for Quantitative Studies was used to assess the methodological quality of the included studies. When possible, results were meta-analyzed using random-effects analysis and rated using GRADE. A total of 11.329 titles/abstracts were screened and 224 were read full text in duplicate, of which 78 studies were included. The pooled prevalence of insomnia (symptoms) in people with T2D was 39% (95%CI:34-44) with I 2 statistic of 100% (P<0.00001), with a very low GRADE of evidence. Sensitivity analyses identified no clear sources of heterogeneity. Meta-analyses showed that in people with T2D, insomnia (symptoms) were associated with higher HbA1c levels (mean difference (MD): 0.23% (0.1-0.4)) and higher fasting glucose levels (MD: 0.40 mmol/l (0.2-0.7)), with a low GRADE of evidence. The relative low methodological quality and high heterogeneity of the studies included in this meta-analysis however complicate the interpretation of our results. The prevalence of insomnia (symptoms) is 39% (95%CI:34-45) in the T2D population and may be associated with deleterious glycemic control.